Lupin has posted steady U.S. growth and a continually expanding pipeline of new products and initiatives since establishing its U.S. base of operations.
Lupin Pharmaceuticals Inc. founded in Baltimore, Maryland for marketing and developmental activities in the U.S.
Generics business launched
Generics business launched in the U.S. with 5 products
5th largest generic manufacturer in the U.S. by prescriptions dispensed
Emerges as the 5th largest manufacturer player in the U.S.
Center of Excellence facility
Lupin announces new Center of Excellence facility for Inhalation Research in Coral Springs, Florida
By acquiring Novel Laboratories, Inc. Lupin created Lupin Somerset, Lupin’s first U.S.- based commercial manufacturing facility
U.S. Revenue exceeds $1 Billion
Fiscal year 2017 marked a milestone for Lupin as our U.S. revenues surpassed the USD 1 billion mark; a growth of 37% over fiscal year 2016 (revenues FY2017 were $1,207 million vs. $883 million in FY2016)
Solosec® (secnidazole) launched
Solosec® (secnidazole) launched in the U.S.
Information provided on this site is intended for use only by residents of United States. The products discussed herein are available only upon prescription from a medical doctor or qualified medical professional. Consumers should not construe any information herein as medical advice or as a substitute for discussions with a prescribing practitioner or other qualified medical professional. Reader understand and agrees to the foregoing.